睿知中国医院研究地图
候选清单

正在招募多发性骨髓瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京大学人民医院Peking University People's Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06514508,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 78 岁;性别:不限

    登记记录的入选字段

  2. Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class >2 or NYHA Heart Failure Class >2.

    排除标准第 32 条

  3. Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception method during the study period and within 90 days after the last study treatment.

    入选标准第 10 条

    Is currently participating and/or receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

    排除标准第 28 条

    Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug.

    排除标准第 36 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

    入选标准第 8 条

  5. Eltrombopag, romiplostim or platelet stimulating agents: 30 days

    排除标准第 13 条

  6. Known human immunodeficiency virus (HIV) or active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive and HBV DNA>500 IU/mL or >2500 copies/mL) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is positive).

    排除标准第 37 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06514508,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. (Limit: 15,000 characters)
  2. Patients must have a signed study informed consent prior to entering the study.
  3. Patients must be between the ages of 18 and 78 years.
  4. Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria.
  5. At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
  6. Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator's discretion.
  7. The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
  8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  9. Adequate organ function at screening.
  10. Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception method during the study period and within 90 days after the last study treatment.

排除标准:Exclusion Criteria:

  1. Previous history of autologous or allogeneic-HCT.
  2. Failed previous HSC collections or collection attempts.
  3. Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
  4. Dexamethasone: 7 days
  5. Thalidomide: 7 days
  6. Lenalidomide: 7 days
  7. Pamolidomide: 7 days
  8. Bortezomib: 7 days
  9. Carfilzomib: 7 days
  10. G-CSF: 14 days
  11. GM-CSF or Neulasta®: 21 days
  12. Erythropoietin or erythrocyte stimulating agents: 30 days
  13. Eltrombopag, romiplostim or platelet stimulating agents: 30 days
  14. Carmustine (BCNU): 42 days/6 weeks
  15. Daratumumab or any other anti-CD38: 28 days
  16. Ixazomib: 7 day.
  17. Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
  18. Received >8 cycles of alkylating agent combinations.
  19. Received > 6 cycles of melphalan.
  20. Received prior treatment with radioimmunotherapy (e.g. radionuclides).
  21. Received prior treatment with venetoclax.
  22. Plans to receive maintenance treatment within 60 days post- transplantation (e.g.lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.).
  23. Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
  24. Known active CNS metastases or carcinomatous meningitis.
  25. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF, or other agents used in the study.
  26. Has an active or uncontrolled infection requiring systemic therapy.
  27. Has a known additional malignancy that is progressing or requires active treatment.
  28. Is currently participating and/or receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  29. O2 saturation < 92% (on room air).
  30. Personal history or family history of Long QT Syndrome or Torsade de Pointes.
  31. History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
  32. Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class >2 or NYHA Heart Failure Class >2.
  33. ECG at screening showing QTcF > 470 msec and/or PR > 280 msec.
  34. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
  35. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  36. Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug.
  37. Known human immunodeficiency virus (HIV) or active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive and HBV DNA>500 IU/mL or >2500 copies/mL) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is positive).
  38. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.

引自 ClinicalTrials.gov, NCT06514508, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06514508,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06514508